OBJECTIVES: Sandostatin^® LAR^® (SAS LAR), an injectable slow-release synthetic octapeptide analogue of somatostatin, is indicated to control symptoms in patients with acromegaly and neuroendocrine tumors (NET). To optimize patients’ experience with SAS LAR, a fully-subsidized Mobile Administration Program (MAP) has been launched by Novartis Pharmaceuticals Inc., which provides home nurse visits for administration/monitoring of SAS LAR every 4 weeks. The objective of this study was to quantify the economic benefit of the MAP in Canada. METHODS: A three-year budget impact model was developed to estimate the net benefit of the MAP from the societal perspective. All patients with acromegaly and NET in Canada who are currently treated with SAS LAR were included. The proportion of patients enrolled in the MAP versus those not enrolled was estimated using national SAS LAR sales data and data collected by the MAP. Costs associated with patients participating versus not participating in the MAP were estimated, with assistance from Canadian clinicians, considering costs of: SAS LAR acquisition and utilization rates, administration/monitoring, treatment non-compliance, and patient time lost for administration/monitoring. The primary outcome was the net difference in cost between the world-with versus world-without MAP. RESULTS: In the current year, it was estimated that 61% of SAS LAR patients in Canada participated in the MAP and, of those, 81% chose to receive home visits. The estimated year 1 savings to society generated by the MAP were $712,000. When MAP participation rates were projected to increase to 100% by year 3, the 3-year cumulative cost savings were estimated at $3,473,000 ($1,171,000 acromegaly; $2,302,000 NET). The largest savings were derived from reduced administration/monitoring costs for MAP patients. CONCLUSIONS: The analysis predicts the MAP is likely to improve treatment compliance while also yielding cost savings.